Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vyome HoldingsHIND +4.02%11 PB Ratio is 2.15 as of Jul. 29, 2026, which is 64% below its 10-year median of 5.90. GuruFocus rates HIND with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,227 Biotechnology companies, Vyome Holdings ranks better than 60.72% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-29), Vyome Holdings's share price is $2.07. Vyome Holdings's Book Value per Share for the quarter that ended in Mar. 2026 was $0.96. Hence, Vyome Holdings's PB Ratio of today is 2.15.
Good Sign:
Vyome Holdings Inc stock PB Ratio (=2.07) is close to 1-year low of 1.97.
The historical rank and industry rank for Vyome Holdings's PB Ratio or its related term are showing as below:
HIND'
s PB Ratio Range Over the Past 10 Years
Min: 1.97 Med: 5.9 Max: 13.3
Current: 2.16
During the past 4 years, Vyome Holdings's highest PB Ratio was 13.30. The lowest was 1.97. And the median was 5.90.
HIND's PB Ratio is ranked better than 60.72% of 1227
companies
in the Biotechnology industry
Industry Median: 2.75
vs HIND: 2.16
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Vyome Holdings PB Ratio Related Terms
Vyome Holdings PB Ratio Historical Data
* Premium members only.
The historical data trend for Vyome Holdings's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vyome Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vyome Holdings PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vyome Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vyome Holdings's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Vyome Holdings's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vyome Holdings (HIND) has a PB Ratio of 2.15 as of Jul. 29, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vyome Holdings and its competitors. This is 64% below median its historical median of 5.90. Over the past decade, Vyome Holdings' PB Ratio has ranged from 1.97 to 13.30. According to the industry distribution chart, Vyome Holdings ranks #482 out of 1227 companies in the Biotechnology industry, placing it in the top 39.3%.
Is Vyome Holdings' PB Ratio too high?
Vyome Holdings' current PB Ratio of 2.15 is 64% below median its 10-year median of 5.90. Over the past 10 years, this metric has ranged from a low of 1.97 to a high of 13.30. The Biotechnology industry median PB Ratio is 2.75. Vyome Holdings' value of 2.15 is 21.8% below this industry median. Based on the distribution chart, Vyome Holdings ranks #482 out of 1227 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vyome Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Vyome Holdings' PB Ratio compare to CTXR and MBRX?
According to the Biotechnology industry distribution chart, Vyome Holdings ranks #482 out of 1227 companies for PB Ratio. This puts Vyome Holdings in the upper half of its industry. The industry median PB Ratio is 2.75. Vyome Holdings' value of 2.15 is 21.8% below this benchmark. Historically, Vyome Holdings' own PB Ratio has ranged from 1.97 to 13.30 over the past decade. While the company's 10-year median is 5.90 vs. the industry median of 2.75, Vyome Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.75, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vyome Holdings's current PB Ratio of 2.15 is 21.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vyome Holdings and its competitors. For the Biotechnology industry, the median PB Ratio is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vyome Holdings's current PB Ratio is 2.15, which is 64% below median its own 10-year median of 5.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vyome Holdings stock overvalued right now?
Vyome Holdings (HIND) has a current PB Ratio of 2.15. The current PB Ratio is 2.15, which is 64% below median its 10-year median of 5.90 and 21.8% below the Biotechnology industry median of 2.75. Vyome Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vyome Holdings (HIND), the current PB Ratio is 2.15 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
11GF Score
Get the complete analysis for HIND
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HIND has been successfully added to your 
